Award for Outstanding Contribution to Translational Medicine
Nominations have now closed for the 2025 recipient.
The winner will be announced at the 118th Annual Meeting at the RCP, London 3-4 April, 2025.
Congratulations to Professor Sir Adrian Hill
Congratulations to Professor Sir Adrian Hill who was announced as the 2024 recipient of the Association of Physicians’ award for an Outstanding Contribution to Translational Medicine. Adrian was presented with the award at a ceremony during the annual meeting held in Newcastle 23-24 May, 2024.
Adrian is the Director and Founder of the Jenner Institute and Mittal Professor of Vaccinology at Oxford University. His group has been one of the leaders in the development of adenoviral and other vaccines against infectious diseases and he has tested these in extensively in clinical trials in Africa and Europe. In partnership with the Serum Institute of India and AstraZeneca the Jenner Institute developed rapidly a ChAdOx1 vector-based SARS-CoV-2 vaccine which saved an estimated 6.2 million lives in 2021 alone. His lab has also designed a new malaria vaccine, R21/Matrix-MTM, which has recently reached licensure, again in partnership with the Serum Institute of India and also Novavax Inc. In 2021 he was elected a Fellow of the Royal Society and appointed an Honorary Knight Commander of the Order of the British Empire (KBE) in Queen Elizabeth’s Birthday Honours. The nomination acknowledges the major contributions Adrian has made to vaccinations globally.
Congratulations to Professor Sir Stephen O’Rahilly
Congratulations to Professor Sir Stephen O’Rahilly who was announced as the 2023 recipient of the Association of Physicians’ award for an Outstanding Contribution to Translational Medicine. Stephen was presented with the award at a ceremony during the annual meeting held in Liverpool 20-21 April, 2023.
The nomination acknowledges the major contributions Stephen has made to the understanding of the molecular mechanisms underlying human disorders of energy balance and metabolism. His work first established that mutations in single genes could result in severe human obesity and that these defects largely acted through the disruption of central satiety mechanisms. These findings have altered clinical approaches to the evaluation of the obese child and have identified a subtype of obesity amenable to dramatically effective therapy. His studies of patients with extreme insensitivity to insulin have also provided new insights into human insulin action and its disruption in states of insulin resistance.